BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 37539769)

  • 1. MFSD2A potentiates gastric cancer response to anti-PD-1 immunotherapy by reprogramming the tumor microenvironment to activate T cell response.
    Zhang B; Wang CM; Wu HX; Wang F; Chai YY; Hu Y; Wang BJ; Yu Z; Xia RH; Xu RH; Cao XT
    Cancer Commun (Lond); 2023 Oct; 43(10):1097-1116. PubMed ID: 37539769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KLF5 inhibition potentiates anti-PD1 efficacy by enhancing CD8
    Wu Q; Liu Z; Gao Z; Luo Y; Li F; Yang C; Wang T; Meng X; Chen H; Li J; Kong Y; Dong C; Sun S; Chen C
    Theranostics; 2023; 13(4):1381-1400. PubMed ID: 36923542
    [No Abstract]   [Full Text] [Related]  

  • 3. PD-1 does not mark tumor-infiltrating CD8+ T cell dysfunction in human gastric cancer.
    Shen Y; Teng Y; Lv Y; Zhao Y; Qiu Y; Chen W; Wang L; Wang Y; Mao F; Cheng P; Ma D; Zhuang Y; Zou Q; Peng L
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32753468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MFSD2A expression predicts better prognosis in gastric cancer.
    Shi X; Huang Y; Wang H; Zheng W; Chen S
    Biochem Biophys Res Commun; 2018 Nov; 505(3):699-704. PubMed ID: 30292405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pectin supplement significantly enhanced the anti-PD-1 efficacy in tumor-bearing mice humanized with gut microbiota from patients with colorectal cancer.
    Zhang SL; Mao YQ; Zhang ZY; Li ZM; Kong CY; Chen HL; Cai PR; Han B; Ye T; Wang LS
    Theranostics; 2021; 11(9):4155-4170. PubMed ID: 33754054
    [No Abstract]   [Full Text] [Related]  

  • 6. Prognostic Significance of PD-1, PD-L1 and CD8 Gene Expression Levels in Gastric Cancer.
    Ito S; Masuda T; Noda M; Hu Q; Shimizu D; Kuroda Y; Eguchi H; Tobo T; Utsunomiya T; Mimori K
    Oncology; 2020; 98(7):501-511. PubMed ID: 32380498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting myeloid checkpoint Siglec-10 reactivates antitumor immunity and improves anti-programmed cell death 1 efficacy in gastric cancer.
    Lv K; Sun M; Fang H; Wang J; Lin C; Liu H; Zhang H; Li H; He H; Gu Y; Li R; Shao F; Xu J
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37935567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-1 inhibitor combined with apatinib modulate the tumor microenvironment and potentiate anti-tumor effect in mice bearing gastric cancer.
    Chen H; Jiang T; Lin F; Guan H; Zheng J; Liu Q; Du B; Huang Y; Lin X
    Int Immunopharmacol; 2021 Oct; 99():107929. PubMed ID: 34343940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical relevance of PD-1 positive CD8 T-cells in gastric cancer.
    Choo J; Kua LF; Soe MY; Asuncion BR; Tan BKJ; Teo CB; Tay RYK; So J; Shabbir A; Guowei K; Tan HL; Chan G; Ma H; Ramachandran GK; Lum JHY; Chee CE; Sridharan S; Tan P; Sundar R; Yong WP
    Gastric Cancer; 2023 May; 26(3):393-404. PubMed ID: 36781556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting inhibition of prognosis-related lipid metabolism genes including CYP19A1 enhances immunotherapeutic response in colon cancer.
    Liu L; Mo M; Chen X; Chao D; Zhang Y; Chen X; Wang Y; Zhang N; He N; Yuan X; Chen H; Yang J
    J Exp Clin Cancer Res; 2023 Apr; 42(1):85. PubMed ID: 37055842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salvia mitiorrhiza Bunge aqueous extract attenuates infiltration of tumor-associated macrophages and potentiates anti-PD-L1 immunotherapy in colorectal cancer through modulating Cox2/PGE2 cascade.
    Song M; Qian C; Zhang T; Tang Y; Zhou Y; Wei Z; Wang A; Zhong C; Zhao Y; Lu Y
    J Ethnopharmacol; 2023 Nov; 316():116735. PubMed ID: 37286115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 14. LSD1 deletion decreases exosomal PD-L1 and restores T-cell response in gastric cancer.
    Shen DD; Pang JR; Bi YP; Zhao LF; Li YR; Zhao LJ; Gao Y; Wang B; Wang N; Wei L; Guo H; Liu HM; Zheng YC
    Mol Cancer; 2022 Mar; 21(1):75. PubMed ID: 35296335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD4
    Xiao M; Xie L; Cao G; Lei S; Wang P; Wei Z; Luo Y; Fang J; Yang X; Huang Q; Xu L; Guo J; Wen S; Wang Z; Wu Q; Tang J; Wang L; Chen X; Chen C; Zhang Y; Yao W; Ye J; He R; Huang J; Ye L
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impacts and mechanisms of metabolic reprogramming of tumor microenvironment for immunotherapy in gastric cancer.
    Zhao L; Liu Y; Zhang S; Wei L; Cheng H; Wang J; Wang J
    Cell Death Dis; 2022 Apr; 13(4):378. PubMed ID: 35444235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blocking LTB
    Yan J; Zhu J; Li X; Yang R; Xiao W; Huang C; Zheng C
    Phytomedicine; 2023 Oct; 119():154968. PubMed ID: 37531900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-cell RNA sequencing reveals the effects of anti-PD-L1 therapy on 3LL lung cancer model and its tumor microenvironment.
    Zhang H; Huang H; Wu S; He X; Chen J; Zheng X; Chen L; Wang Z
    Med Oncol; 2023 Aug; 40(10):285. PubMed ID: 37653265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer.
    Kim K; Park S; Park SY; Kim G; Park SM; Cho JW; Kim DH; Park YM; Koh YW; Kim HR; Ha SJ; Lee I
    Genome Med; 2020 Feb; 12(1):22. PubMed ID: 32111241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An antigen processing and presentation signature for prognostic evaluation and immunotherapy selection in advanced gastric cancer.
    Wang KW; Wang MD; Li ZX; Hu BS; Wu JJ; Yuan ZD; Wu XL; Yuan QF; Yuan FL
    Front Immunol; 2022; 13():992060. PubMed ID: 36311733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.